# Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements

Source: https://onco.cc/trials/nct05987644/  
OnCo record `nct05987644` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of alectinib in lung cancer, run by Joshua Palmer, now recruiting.

## Summary

Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements is a phase 1/2, randomised interventional study registered as NCT05987644 by Joshua Palmer, with a registry enrolment figure of 56 participants, started 2024-03-07 and due to reach its primary completion in 2028-02-28. Interventions recorded: Alectinib; Stereotactic Radiosurgery. Conditions listed: Lung Cancer; NSCLC; Brain Metastases. Primary outcome: Phase 2: Neurological status and control of CNS disease at 12 months compared to alectinib plus SRS in patients with ≤15 CNS metastases; Phase 1b: Safety and Feasibility. Lung eligibility wording from the registry: "Histological or cytological confirmation of Stage IV (per AJCC 8th edition) non-small cell lung cancer (NSCLC)". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: DURABLE
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT05987644
- Phase: 1/2
- Setting: DURABLE: Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and rEarrangements
- Sponsor: Joshua Palmer
- Enrolled: 56

## Sources

- ClinicalTrials.gov NCT05987644: https://clinicaltrials.gov/study/NCT05987644

## Connected records

- cancers: [ALK-positive non-small-cell lung cancer](https://onco.cc/cancers/alk-positive-nsclc/)
- technologies: [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Alectinib](https://onco.cc/drugs/alectinib/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05987644.json